Recursion Pharmaceuticals, a clinical-stage TechBio company, announced updated pipeline guidance, projecting seven clinical trial readouts within approximately 18 months. The announcement was made during Recursion's Download Day, an investor and R&D event held on Monday, June 24, 2024.
Pipeline Updates
The company's pipeline advancements include several key clinical milestones:
- REC-994 (Cerebral Cavernous Malformation): Topline Phase 2 data readout expected in September 2024.
- REC-2282 (Neurofibromatosis Type 2): Preliminary Phase 2 data readout anticipated in the fourth quarter of 2024.
- REC-4881 (Familial Adenomatous Polyposis): Preliminary Phase 2 data readout expected in the first half of 2025.
- REC-4881 (Advanced AXIN1/APC-Mutant Cancers): Preliminary Phase 2 data readout anticipated in the first half of 2025.
- REC-3964 (Clostridioides difficile Infection): Phase 2 study initiation in the fourth quarter of 2024, with preliminary data readout by the end of 2025.
- RBM39 (Advanced HR-Proficient Cancers): IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024, and Phase 1 dose-escalation data readout by the end of 2025.
- Target Epsilon (Fibrotic Diseases): IND submission in early 2025, with Phase 1 healthy volunteer study data readout by the end of 2025.
Chris Gibson, Ph.D., Co-Founder and CEO of Recursion, stated, "Over the past decade, we have created a strong leadership position by building the technological and operational capabilities of our platform in order to expand and advance our internal pipeline as well as deliver for our external partners through the integrated use of data, compute, and automation."
Bayer Partnership
Recursion is expanding its partnership with Bayer, with Bayer becoming the first external beta-user of Recursion’s LOWE (LLM-Orchestrated Workflow Engine) software. This integration aims to provide a more exploratory and intuitive research environment for scientists.
Additional partnership updates include the initiation of a joint oncology project expected to advance rapidly towards Lead Series nomination. Recursion is also on track to complete 25 unique multi-modal data packages for Bayer in the third quarter of 2024.
Platform Advancements
Recursion highlighted advancements in its platform capabilities, including:
- ADME industrialization with the potential to achieve an estimated 90 times the amount of lab throughput over a manual approach.
- The creation of its first genome-scale transcriptomics knockout map.
- Multimodal mapping achieving 90% success in predicting compounds that failed later disease-relevant assays and 60% success in predicting compounds that passed later disease-relevant assays in internal tests.
Recursion's platform leverages a vast dataset and machine learning algorithms to identify relationships across biology and chemistry, aiming to accelerate drug discovery. The company's experimental scale includes millions of wet lab experiments weekly, supported by a high-performance supercomputer.
